Literature DB >> 25400280

BRCA1, a 'complex' protein involved in the maintenance of genomic stability.

Kienan I Savage1, D Paul Harkin.   

Abstract

BRCA1 is a major breast and ovarian cancer susceptibility gene, with mutations in this gene predisposing women to a very high risk of developing breast and ovarian tumours. BRCA1 primarily functions to maintain genomic stability via critical roles in DNA repair, cell cycle checkpoint control, transcriptional regulation, apoptosis and mRNA splicing. As a result, BRCA1 mutations often result in defective DNA repair, genomic instability and sensitivity to DNA damaging agents. BRCA1 carries out these different functions through its ability to interact, and form complexes with, a vast array of proteins involved in multiple cellular processes, all of which are considered to contribute to its function as a tumour suppressor. This review discusses and highlights recent research into the functions of BRCA1-related protein complexes and their roles in maintaining genomic stability and tumour suppression.
© 2014 FEBS.

Entities:  

Keywords:  BRCA1; DNA damage response; DNA repair; breast cancer; genomic instability; hereditary breast cancer

Mesh:

Substances:

Year:  2014        PMID: 25400280     DOI: 10.1111/febs.13150

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  60 in total

Review 1.  Centrosomes in the DNA damage response--the hub outside the centre.

Authors:  Lisa I Mullee; Ciaran G Morrison
Journal:  Chromosome Res       Date:  2016-01       Impact factor: 5.239

2.  DNA Repair Network Analysis Reveals Shieldin as a Key Regulator of NHEJ and PARP Inhibitor Sensitivity.

Authors:  Rajat Gupta; Kumar Somyajit; Takeo Narita; Elina Maskey; Andre Stanlie; Magdalena Kremer; Dimitris Typas; Michael Lammers; Niels Mailand; Andre Nussenzweig; Jiri Lukas; Chunaram Choudhary
Journal:  Cell       Date:  2018-04-12       Impact factor: 41.582

Review 3.  Dietary fat and obesity as modulators of breast cancer risk: Focus on DNA methylation.

Authors:  Micah G Donovan; Spencer N Wren; Mikia Cenker; Ornella I Selmin; Donato F Romagnolo
Journal:  Br J Pharmacol       Date:  2020-01-26       Impact factor: 8.739

4.  Dissenting degradation: Deubiquitinases in cell cycle and cancer.

Authors:  Thomas Bonacci; Michael J Emanuele
Journal:  Semin Cancer Biol       Date:  2020-03-20       Impact factor: 15.707

5.  BRCA1 recruitment to damaged DNA sites is dependent on CDK9.

Authors:  Thales C Nepomuceno; Vanessa C Fernandes; Thiago T Gomes; Renato S Carvalho; Guilherme Suarez-Kurtz; Alvaro N Monteiro; Marcelo A Carvalho
Journal:  Cell Cycle       Date:  2017-02-22       Impact factor: 4.534

Review 6.  Maintenance of genome stability: the unifying role of interconnections between the DNA damage response and RNA-processing pathways.

Authors:  B Mikolaskova; M Jurcik; I Cipakova; M Kretova; M Chovanec; L Cipak
Journal:  Curr Genet       Date:  2018-03-01       Impact factor: 3.886

7.  Homologous Recombination Repair Factors Rad51 and BRCA1 Are Necessary for Productive Replication of Human Papillomavirus 31.

Authors:  William H Chappell; Dipendra Gautam; Suzan T Ok; Bryan A Johnson; Daniel C Anacker; Cary A Moody
Journal:  J Virol       Date:  2015-12-23       Impact factor: 5.103

8.  Germline Variants and Risk for Pancreatic Cancer: A Systematic Review and Emerging Concepts.

Authors:  Wei Zhan; Celeste A Shelton; Phil J Greer; Randall E Brand; David C Whitcomb
Journal:  Pancreas       Date:  2018-09       Impact factor: 3.327

Review 9.  RAP80, ubiquitin and SUMO in the DNA damage response.

Authors:  Patrick M Lombardi; Michael J Matunis; Cynthia Wolberger
Journal:  J Mol Med (Berl)       Date:  2017-07-05       Impact factor: 4.599

10.  The putative oncogene CEP72 inhibits the mitotic function of BRCA1 and induces chromosomal instability.

Authors:  S Lüddecke; N Ertych; A Stenzinger; W Weichert; T Beissbarth; J Dyczkowski; J Gaedcke; O Valerius; G H Braus; M Kschischo; H Bastians
Journal:  Oncogene       Date:  2015-08-24       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.